Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01854606
Title Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
Acronym COEB071X2103
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult
Covered Countries USA | NLD | ITA | FRA | DEU

Facility Status City State Zip Country Details
Washington University School of Medicine Dept of Oncology. Saint Louis Missouri 63110 United States Details
Memorial Sloan Kettering Cancer Center Onc. Dept. New York New York 10065 United States Details
Sarah Cannon Research Institute Dept of Onc Nashville Tennessee 37203 United States Details
Novartis Investigative Site Rouen Cedex 1 76038 France Details
Novartis Investigative Site Mainz 55131 Germany Details
Novartis Investigative Site Muenchen 81377 Germany Details
Novartis Investigative Site Hong Kong Hong Kong Details
Novartis Investigative Site New Territories Hong Kong Details
Novartis Investigative Site Milano MI 20133 Italy Details
Novartis Investigative Site Milano MI 20141 Italy Details
Novartis Investigative Site Seoul Korea 03080 Korea, Republic of Details
Novartis Investigative Site Seoul Korea 06351 Korea, Republic of Details
Novartis Investigative Site Rotterdam 3015 CE Netherlands Details
Novartis Investigative Site Rotterdam 3075 EA Netherlands Details
Novartis Investigative Site Taipei 10002 Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field